{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:30:53Z","timestamp":1787020253752,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T00:00:00Z","timestamp":1680048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T00:00:00Z","timestamp":1680048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Programmed death-1 (PD-1) and T cell immunoglobulin and mucin-domain-containing molecule 3(Tim-3) may be used as the biomarkers for the therapy in patients with peritoneal neoplasms. In the current study, the differential percentages of peripheral PD-1 and Tim-3 are explored to investigate whether to associate with primary sites and pathological types of patients with peritoneal neoplasms or not. We also investigated the frequencies of PD-1 and Tim-3 on circulating Lymphocytes, CD3\u2009+\u2009T cells, CD3\u2009+\u2009CD4\u2009+\u2009T cells and CD3\u2009+\u2009CD8\u2009+\u2009T cells if would correlate with the progression-free survival of peritoneal neoplasms patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>115 patients with peritoneal neoplasms were recruited, subjected to multicolor flow cytometric analyses of the percentages of PD-1 and Tim-3 receptors of circulating Lymphocytes, CD3\u2009+\u2009T cells, CD3\u2009+\u2009CD4\u2009+\u2009T cells and CD3\u2009+\u2009CD8\u2009+\u2009T cells. The peritoneal neoplasms patients were divided into primary group and secondary group depending on whether the tumor had primary focus and limited to peritoneal tumor or not. Then all the patients were regrouped by the pathological types of neoplasms (adenocarcinoma, mesothelioma, and pseudomyxoma). The secondary peritoneal neoplasms group was divided into the different primary site groups (colon, gastric, gynecology). This study also enrolled 38 cases of normal volunteers. The above markers were explored by flow cytometer, to find the differential levels in peritoneal neoplasms patients compared with normal group in peripheral blood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Higher levels of CD4\u2009+\u2009T lymphocytes, CD8\u2009+\u2009T lymphocytes, CD45\u2009+\u2009PD-1\u2009+\u2009lymphocytes, CD3\u2009+\u2009PD-1\u2009+\u2009T cells, CD3\u2009+\u2009CD4\u2009+\u2009PD-1\u2009+\u2009T cells, CD3\u2009+\u2009CD8\u2009+\u2009PD-1\u2009+\u2009T cells and CD45\u2009+\u2009Tim-3\u2009+\u2009lymphocytes were found in peritoneal neoplasms group than normal control (the p value was respectively 0.004, 0.047, 0.046, 0.044, 0.014, 0.038 and 0.017). Compared with primary peritoneal neoplasms group, the percentages of CD45\u2009+\u2009PD-1\u2009+\u2009lymphocytes, CD3\u2009+\u2009PD-1\u2009+\u2009T cells, and CD3\u2009+\u2009CD4\u2009+\u2009PD-1\u2009+\u2009T cells were increased in the secondary peritoneal neoplasms group (the p value was respectively 0.010, 0.044, and 0.040), while PD-1 did not correlate with the primary sites in secondary group (P\u2009&gt;\u20090.05). Tim-3 had no statistical differences in primary peritoneal neoplasms group compared with secondary group (p\u2009&gt;\u20090.05), but CD45\u2009+\u2009Tim-3+% lymphocytes, CD3\u2009+\u2009Tim-3+%T cells, and CD3\u2009+\u2009CD4\u2009+\u2009Tim-3\u2009+\u2009T cells were associated with different secondary sites of peritoneal neoplasms (p\u2009&lt;\u20090.05). In the different pathological type groups, the percentages of CD45\u2009+\u2009PD-1\u2009+\u2009lymphocytes, CD3\u2009+\u2009PD-1\u2009+\u2009T cells presented the higher levels in adenocarcinoma group compared with mesothelioma group (p\u2009=\u20090.048, p\u2009=\u20090.045). The frequencies of CD45\u2009+\u2009PD-1\u2009+\u2009lymphocytes and CD3\u2009+\u2009PD-1\u2009+\u2009T cells in peripheral blood were associated with progression-free survival (PFS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our work uncovers peripheral PD-1 and Tim-3 percentages are associated with primary sites and pathological types of peritoneal neoplasms. Those findings might provide important assessment to predict peritoneal neoplasms patients\u2019 immunotherapy responses.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-023-10752-2","type":"journal-article","created":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T06:02:52Z","timestamp":1680069772000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Peripheral PD-1 and Tim-3 percentages are associated with primary sites and pathological types of peritoneal neoplasms"],"prefix":"10.1186","volume":"23","author":[{"given":"Huihui","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,29]]},"reference":[{"issue":"10","key":"10752_CR1","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1002\/bjs.11301","volume":"106","author":"Y Baba","year":"2019","unstructured":"Baba Y, Yagi T, Kosumi K, et al. Morphological lymphocytic reaction, patient prognosis and PD-1 expression after surgical resection for oesophageal cancer. Br J Surg. 2019;106(10):1352\u201361.","journal-title":"Br J Surg"},{"issue":"5","key":"10752_CR2","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S1471-4906(01)01888-9","volume":"22","author":"H Nishimura","year":"2015","unstructured":"Nishimura H, Honjo T. PD-1: an inhibitory immunoreceptor involved in peripheral tolerance. Trends Immunol. 2015;22(5):265\u20138.","journal-title":"Trends Immunol"},{"key":"10752_CR3","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.biopha.2018.11.105","volume":"110","author":"N Yaghoubi","year":"2019","unstructured":"Yaghoubi N, Soltani A, Ghazvini K, Hassanian SM, Hashemy SI. PD-1\/PD-L1 blockade as a novel treatment for colorectal cancer. Biomed Pharmacother. 2019;110:312\u20138.","journal-title":"Biomed Pharmacother"},{"key":"10752_CR4","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrc.2016.36","volume":"16","author":"SL Topalian","year":"2016","unstructured":"Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat RevCancer. 2016;16:275\u201387.","journal-title":"Nat RevCancer"},{"key":"10752_CR5","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P. etal.Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455\u201365.","journal-title":"N Engl J Med"},{"key":"10752_CR6","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ctrv.2017.01.007","volume":"54","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, Powles T, Vogelzang NJ. A review on the evolution of PD-1\/PD-L1 immunotherapy for bladder cancer: the future is now. Cancer Treat Rev. 2017;54:58\u201367.","journal-title":"Cancer Treat Rev"},{"key":"10752_CR7","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320\u201330.","journal-title":"N Engl J Med"},{"issue":"1","key":"10752_CR8","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/s41467-021-21099-2","volume":"5","author":"R Yang","year":"2021","unstructured":"Yang R, Sun L, Li C-F, et al. Galectin-9 interacts with PD-1 and Tim-3 to regulate T cell death and is a target for cancer immunotherapy. Nat Communication. 2021;5(1):832.","journal-title":"Nat Communication"},{"issue":"11","key":"10752_CR9","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1038\/ni987","volume":"4","author":"A Sanchez-Fueyo","year":"2003","unstructured":"Sanchez-Fueyo A, Tian J, Picarella D, Domenig C, Zheng XX, Sabatos CA, Manlongat N, Bender O, Kamradt T, Kuchroo VK, et al. Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. Nat Immunol. 2003;4(11):1093\u2013101.","journal-title":"Nat Immunol"},{"issue":"12","key":"10752_CR10","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1084\/jem.20081398","volume":"205","author":"RB Jones","year":"2008","unstructured":"Jones RB, Ndhlovu LC, Barbour JD, Sheth PM, Jha AR, Long BR, Wong JC, Satkunarajah M, Schweneker M, Chapman JM, et al. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med. 2008;205(12):2763\u201379.","journal-title":"J Exp Med"},{"issue":"4","key":"10752_CR11","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.4049\/jimmunol.1400557","volume":"193","author":"RL Ferris","year":"2014","unstructured":"Ferris RL, Lu B, Kane LP. Too much of a good thing? Tim-3 and TCR Signaling in T cell exhaustion. J Immunol. 2014;193(4):1525\u201330.","journal-title":"J Immunol"},{"key":"10752_CR12","doi-asserted-by":"publisher","first-page":"61336","DOI":"10.18632\/oncotarget.11038","volume":"7","author":"K Auer","year":"2015","unstructured":"Auer K, et al. Role of the immune system in the peritoneal tumor spread of high grade serous ovarian cancer. Oncotarget. 2015;7:61336\u201354.","journal-title":"Oncotarget"},{"key":"10752_CR13","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.immuni.2016.04.023","volume":"44","author":"MK Callahan","year":"2016","unstructured":"Callahan MK, Postow MA, Wolchok JD. Targeting T cell co-receptor for cancer therapy. Immunity. 2016;44:1069\u201378.","journal-title":"Immunity"},{"key":"10752_CR14","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, PazAres L, Horn L, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373:1627\u201339.","journal-title":"N Engl J Med"},{"key":"10752_CR15","doi-asserted-by":"publisher","first-page":"5461","DOI":"10.1158\/1078-0432.CCR-15-2839","volume":"22","author":"TK Choueiri","year":"2016","unstructured":"Choueiri TK, Fishman MN, Escudier B, et al. Immunomodulatory activity of Nivolumab in metastatic renal cell carcinoma. Clin Cancer Res. 2016;22:5461\u201371.","journal-title":"Clin Cancer Res"},{"key":"10752_CR16","doi-asserted-by":"publisher","first-page":"6400","DOI":"10.1038\/s41598-021-85966-0","volume":"11","author":"C Bekos","year":"2021","unstructured":"Bekos C, Pils D, Dekan S, et al. PD-1 and PD-L1 expression on TILs in peritoneal metastases compared to ovarian tumor tissues and its associations with clinical outcome. Sci Rep. 2021;11:6400\u201312.","journal-title":"Sci Rep"},{"key":"10752_CR17","doi-asserted-by":"publisher","first-page":"e000911","DOI":"10.1136\/jitc-2020-000911","volume":"8","author":"C Nandini Acharya","year":"2020","unstructured":"Nandini Acharya C, Sabatos-Peyton AC, Anderson. Tim-3 finds its place in the cancer immunotherapy landscape. J Immunother Cancer. 2020;8:e000911.","journal-title":"J Immunother Cancer"},{"key":"10752_CR18","first-page":"5294043","volume":"4","author":"W Kuai","year":"2020","unstructured":"Kuai W, Xu X. Prognosisc Impact of PD-1 and Tim-3 expression in Tumor tissue in Stage I-III Colorectal Cancer. Biomed Res Int. 2020;4:5294043.","journal-title":"Biomed Res Int"},{"key":"10752_CR19","doi-asserted-by":"crossref","unstructured":"Zhang Y, Kang S, Shen J et al. Prognostic significance of programmed cell death1 (PD-1) or PD-1 ligand1 (PD-L1) expression in epithelial- originated cancer, Medicineol.2015;94, (6)e515.","DOI":"10.1097\/MD.0000000000000515"},{"key":"10752_CR20","doi-asserted-by":"crossref","unstructured":"Lussier DM, Johnson JL, Hingorani P et al. Combination immunotherapy with \u03b1-CTLA-4 and \u03b1-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma. Journal for immunotherapy of cancer. 2015;3. (1).","DOI":"10.1186\/s40425-015-0067-z"},{"issue":"3","key":"10752_CR21","first-page":"883","volume":"24","author":"N Tsoukalas","year":"2019","unstructured":"Tsoukalas N, Kiakou M, Tsapakidis K, et al. PD-1andPDL1asimmunotherapytargetsandbiomarkersinnon-small cell lung cancer. J BUON. 2019;24(3):883\u20138.","journal-title":"J BUON"},{"key":"10752_CR22","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41586-018-0206-z","volume":"558","author":"N Chihara","year":"2018","unstructured":"Chihara N, Madi A, Kondo T, et al. Induction and transcriptional regulation of the co-\u00adinhibitory gene module in T cells. Nature. 2018;558:454\u20139.","journal-title":"Nature"},{"key":"10752_CR23","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4049\/immunohorizons.1800083","volume":"3","author":"JH DeLong","year":"2019","unstructured":"DeLong JH, O\u2019Hara Hall A, Rausch M, et al. Il-27 and TCR stimulation promote T cell expression of multiple inhibitory receptors. ImmunoHorizons. 2019;3:13\u201325.","journal-title":"ImmunoHorizons"},{"key":"10752_CR24","doi-asserted-by":"publisher","first-page":"10501","DOI":"10.1038\/ncomms10501","volume":"7","author":"AkbayEA KoyamaS","year":"2016","unstructured":"KoyamaS AkbayEA. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 2016;7:10501.","journal-title":"Nat Commun"},{"key":"10752_CR25","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nrclinonc.2016.40","volume":"13","author":"D Romero","year":"2016","unstructured":"Romero D, Immunotherapy. PD-1 says goodbye, TIM-3 says hello. Nat Rev Clin Oncol. 2016;13:202\u20133.","journal-title":"Nat Rev Clin Oncol"},{"key":"10752_CR26","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1084\/jem.20100643","volume":"207","author":"K Sakuishi","year":"2010","unstructured":"Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD\u20101 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med. 2010;207:2187\u201394.","journal-title":"J Exp Med"},{"key":"10752_CR27","doi-asserted-by":"publisher","first-page":"4501","DOI":"10.1182\/blood-2010-10-310425","volume":"117","author":"Q Zhou","year":"2011","unstructured":"Zhou Q, Munger ME, Veenstra RG, et al. Co-expression of Tim-3 and PD\u20101 identifies a CD8 + T\u2010cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood. 2011;117:4501\u201310.","journal-title":"Blood"},{"key":"10752_CR28","doi-asserted-by":"publisher","first-page":"14733","DOI":"10.1073\/pnas.1009731107","volume":"107","author":"HT Jin","year":"2010","unstructured":"Jin HT, Anderson AC, Tan WG, et al. Cooperation of Tim-3 and PD\u20101 in CD8 T\u2010cell exhaustion during chronic viral infection. Proc Natl Acad Sci U S A. 2010;107:14733\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10752_CR29","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","volume":"26","author":"ME Keir","year":"2008","unstructured":"Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26(1):677\u2013704.","journal-title":"Annu Rev Immunol"},{"issue":"8","key":"10752_CR30","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.it.2011.05.003","volume":"32","author":"K Sakuishi","year":"2011","unstructured":"Sakuishi K, Jayaraman P, Behar SM, Anderson AC, et al. Emerging Tim-3 functions in anti-microbial and tumor immunity. Trends Immunol. 2011;32(8):345\u20139.","journal-title":"Trends Immunol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-023-10752-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-023-10752-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-023-10752-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T06:04:54Z","timestamp":1680069894000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-023-10752-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,29]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["10752"],"URL":"https:\/\/doi.org\/10.1186\/s12885-023-10752-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,29]]},"assertion":[{"value":"14 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki. This study was in line with the laws and regulations of medical research and has been approved by the Ethic Committee of the Beijing Shijitan Hospital of Capital Medical University. Informed written consent was obtained from all of the children and\/or parents before study inclusion.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"287"}}